Background Diabetes and elevated blood glucose have been associated with increased risk
of atrial fibrillation in a number of epidemiological studies, however, the findings have not …

Objectives To examine the association between dipeptidyl peptidase-4 (DPP-4) inhibitors
and the risk of heart failure or hospital admission for heart failure in patients with type 2 …

ABSTRACT Introduction: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are generally
considered as glucose-lowering agents with a safe profile in type 2 diabetes. Areas covered …

Thiazolidinedione (TZD) drugs used in the treatment of type 2 diabetes mellitus (T2DM)
have proven effective in improving insulin sensitivity, hyperglycemia, and lipid metabolism …

Background Several antidiabetic drugs (ie, sulfonylureas; SU, rosiglitazone) have been
reported to be associated with increased risks of cardiovascular diseases (CVD) in patients …

Purpose Although recent reports suggest an association between saxagliptin and an
increased risk of admissions for heart failure, it is not clear whether dipeptidyl peptidase IV …

Background The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on heart failure
remains uncertain. We therefore conducted a systematic review to assess the possible …

Background: Clinical trials assessing the combination therapy of metformin plus dipeptidyl
peptidase-4 inhibitors versus metformin plus Sulfonylureas on risk of cardiovascular …

Heart failure (HF) affects approximately 5.1 million adults in the USA, with expectations of a
rise to nearly 8 million adults by 2030. Patients with HF are at increased risk for …

Aims Dipeptidyl peptidase 4 inhibitors (DPP4is) are suggested as a second‐and third‐line
antidiabetic treatment for type 2 diabetes. Previous studies assessed only the cardiovascular …